Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
Public ClinicalTrials.gov record NCT04857112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.
Study identification
- NCT ID
- NCT04857112
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 322 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2021 (Actual)
- Primary completion
- Sep 3, 2024 (Actual)
- Completion
- Nov 8, 2024 (Actual)
- Last update posted
- Sep 9, 2025
2021 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 11
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bausch Site 025 | Chandler | Arizona | 85225 | — |
| Salix Site 004 | Los Angeles | California | 90048 | — |
| Salix Site 003 | Rancho Cucamonga | California | 91730 | — |
| Salix Site 007 | Rialto | California | 92377 | — |
| Salix Site 006 | Ventura | California | 93003 | — |
| Bausch Site 013 | Maitland | Florida | 32751 | — |
| Bausch Site 024 | Miami | Florida | 33174 | — |
| Salix Site 005 | Miramar | Florida | 33027 | — |
| Bausch site 026 | Orlando | Florida | 32807 | — |
| Salix Site 010 | Snellville | Georgia | 30078 | — |
| Bausch Site 011 | Chicago | Illinois | 60637 | — |
| Bausch Site 020 | Glenview | Illinois | 60026 | — |
| Bausch Site 008 | Lafayette | Louisiana | 70503 | — |
| Bausch Site 022 | Metairie | Louisiana | 70006 | — |
| Salix Site 001 | Shreveport | Louisiana | 71103 | — |
| Salix Site 002 | Freehold | New Jersey | 07728 | — |
| Bausch Site 017 | Mentor | Ohio | 44060 | — |
| Bausch Site 021 | Oklahoma City | Oklahoma | 73101 | — |
| Bausch Site 014 | El Paso | Texas | 79905 | — |
| Bausch Site 018 | Houston | Texas | 77030 | — |
| Bausch Site 019 | Houston | Texas | 77030 | — |
| Bausch Site 012 | Suffolk | Virginia | 23435 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 163 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04857112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2025 · Synced Oct 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04857112 live on ClinicalTrials.gov.